DMAC DiaMedica Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-26.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-100.2%
ROA-86.3%
ROIC (approx.)-94.2%
Asset turnover—
Leverage & solvency
Liabilities / assets20.7%
Debt / equity0.00x
Current ratio4.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $24.61M | $19.06M | $13.11M | $7.84M | $8.77M |
| SG&A expense | $9.78M | $7.62M | $8.16M | $6.16M | $4.88M |
| Operating income | -$34.40M | -$26.68M | -$21.27M | -$14.00M | -$13.65M |
| Pretax income | -$32.74M | -$24.41M | -$19.34M | -$13.65M | -$13.56M |
| Income tax | $28,000 | $30,000 | $43,000 | $28,000 | $28,000 |
| Net income | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -$13.59M |
| EBITDA | -$34.35M | -$26.64M | -$21.24M | -$13.98M | -$13.62M |
| EPS (basic) | -0.70 | -0.60 | -0.60 | -0.52 | -0.65 |
| EPS (diluted) | — | — | — | — | -0.65 |
| Weighted avg. shares (diluted) | — | — | — | — | 20.77M |
| Balance sheet | |||||
| Cash & equivalents | $15.65M | $3.02M | $4.54M | $4.73M | $4.71M |
| Short-term investments | $44.24M | $41.12M | $48.35M | $28.77M | $40.41M |
| Receivables | $258,000 | $236,000 | $369,000 | $82,000 | $130,000 |
| Current assets | $60.63M | $44.61M | $53.67M | $33.84M | $45.44M |
| PP&E, net | $145,000 | $148,000 | $131,000 | $136,000 | $70,000 |
| Total assets | $61.37M | $46.34M | $54.16M | $34.40M | $45.55M |
| Current liabilities | $5.13M | $5.39M | $2.79M | $2.17M | $1.52M |
| Total liabilities | $5.26M | $5.63M | $3.10M | $2.57M | $1.53M |
| Shareholders' equity | $56.11M | $40.72M | $51.06M | $31.83M | $44.02M |
| Shares outstanding | 53.74M | 42.82M | 37.96M | 26.44M | 26.44M |
| Cash flow statement | |||||
| Operating cash flow | -$29.06M | -$22.08M | -$18.73M | -$11.51M | -$12.25M |
| Capital expenditure | $40,000 | $25,000 | $24,000 | $81,000 | $22,000 |
| Free cash flow | -$29.10M | -$22.10M | -$18.75M | -$11.59M | -$12.27M |
| Investing cash flow | -$2.19M | $8.56M | -$18.30M | $11.54M | -$20.54M |
| Financing cash flow | $43.88M | $11.99M | $36.84M | -$6,000 | $30.09M |
| Depreciation & amortization | $43,000 | $39,000 | $30,000 | $25,000 | $24,000 |
| Stock-based compensation | $3.85M | $2.08M | $1.68M | $1.50M | $1.56M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.